InnoCare Pharma Limited

Equities

9969

KYG4783B1032

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:28 2024-05-20 am EDT			5-day change	1st Jan Change
5.07 ^HKD	-0.59%		-1.74%	-26.42%

May. 16	InnoCare Pharma Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis	CI
May. 14	Innocare Pharma Posts Q1 Loss	MT

InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended December 31, 2021

February 23, 2022 at 08:27 am EST

InnoCare Pharma Limited provided earnings guidance for the year ended December 31, 2021. For the period, the group expects to record a consolidated net loss of not more than approximately RMB 100 million as compared with a consolidated net loss of approximately RMB 464 million for the same period in 2020.

Latest news about InnoCare Pharma Limited

InnoCare Pharma Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis	May. 15	CI
Innocare Pharma Posts Q1 Loss	May. 14	MT
InnoCare Logs Loss in Q1	May. 13	MT
InnoCare Pharma Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
InnoCare Pharma Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib	Mar. 28	CI
Transcript : InnoCare Pharma Limited, 2023 Earnings Call, Mar 28, 2024	Mar. 28
InnoCare Pharma Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
InnoCare Pharma Limited Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China	Mar. 12	CI
InnoCare to Shrink Loss in 2023	Jan. 29	MT
InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023	Jan. 29	CI
InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China	Jan. 23	CI
InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area's Early Access Program	Jan. 21	CI
InnoCare Pharma Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA	Jan. 16	CI
Transcript : InnoCare Pharma Limited Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 08:30 AM	Jan. 10
InnoCare Elects CFO	Dec. 18	MT
InnoCare Pharma Provides Results of Phase 2 Trial for Atopic Dermatitis Medication; Shares Rise 4%	Dec. 17	MT
InnoCare Pharma Appoints Xin Fu as Chief Financial Officer	Dec. 17	CI
InnoCare Pharma Limited Announces the Positive Top-Line Results from the Phase II Randomized, Double-Blind, Placebo-Controlled Study of ICP-332	Dec. 17	CI
InnoCare Pharma Announces Latest Data of Oncology Pipelines Presented at the 65th Annual Meeting of ASH	Dec. 10	CI
InnoCare Pharma Logs 109 Million Yuan Loss in Q3	Nov. 14	MT
InnoCare Pharma Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 13	CI
InnoCare Pharma Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatment of ITP in China	23-10-26	CI
Innocare Pharma Limited Announces the Appointment of Dandan Dong as Independent Non-Executive Director	23-10-11	CI
RemeGen Names CFO	23-09-28	MT
InnoCare Pharma Limited(SHSE:688428) added to Shanghai Stock Exchange Composite Index	23-09-26	CI

Chart InnoCare Pharma Limited

Duration

Period

More charts

Company Profile

InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with large unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal B cell or T cell function. The Company mainly conducts its businesses in domestic and overseas markets.

Sector

Biotechnology & Medical Research

Calendar

2024-06-26 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for InnoCare Pharma Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.721 CNY

Average target price

9.045 CNY

Spread / Average Target

+91.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INNOCARE PHARMA LIMITED	-26.42%	1.28B
VERTEX PHARMACEUTICALS INCORPORATED	+9.46%	115B
REGENERON PHARMACEUTICALS, INC.	+11.79%	106B
ARGENX SE	-3.17%	21.96B
BIONTECH SE	-14.34%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-3.88%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+6.52%	14.32B
SAREPTA THERAPEUTICS, INC.	+35.29%	12.42B

Bio Therapeutic Drugs